Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nippon Shinyaku Co., Ltd.

https://www.nippon-shinyaku.co.jp/english/

Latest From Nippon Shinyaku Co., Ltd.

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

Commercial Approvals

Two New Vaccines Join COVID Fight As China Ships Millions Overseas

CanSino's adenovirus-based COVID-19 vaccine, along with another one from state-owned Sinopharm grab promot approvals in China as  Beijing shipping millions of doses around the world.

China Coronavirus COVID-19

Coronavirus Update: EU Demands AstraZeneca Meets Its Vaccines Commitments After Supply Warning

Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic. 

Commercial Companies

China Sees No Variant Impact On Vaccines, Builds New mRNA Plant

Chinese officials do not expect the new strain of coronavirus emerging in the UK to impact the efficacy of inactivated virus vaccines on the cusp of conditional approval. Meanwhile, a new plant is under construction in China for domestically developed mRNA vaccines.

China Coronavirus COVID-19
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • NS Pharma, Inc.
UsernamePublicRestriction

Register